

PRESS RELEASE Paris, 28 November 2024, 6:00 a.m.

bonyf expands its global NitrAdine® formulation footprint through its latest strategic alliance achievement with Group Pharmaceuticals Ltd, by a license agreement to produce NitrAdine® denture cleansing and disinfecting tablets for India



Knokke-Heist (Belgium), 28 November 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production, and marketing of oral, denture, orthodontic, and wound care products. bonyf NV and Group pharmaceuticals Ltd are pleased to announce a strategic alliance with a license agreement on the NitrAdine® formulation to manufacture and distribute in India the bonyf products NitrAdine® denture cleansing & disinfecting tablets.

bonyf NV is a Belgian company with its R&D department in Liechtenstein and its manufacturing facility in Switzerland founded in 1979 moves forward with its fast global expanding coverage. The innovative driven bonyf R&D department, bonyf AG based in Liechtenstein, develops unique, patented healthy denture fixative creams and the most efficient disinfecting denture tablets based on extensive clinical evidence. The manufacturing facility bonyf Production AG ensures the production of denture products according to the highest worldwide standards. bonyf Regulatory department excels in global regulatory expertise and successful registration support services. The bonyf group offers customers worldwide, products in the oral care segments of removable oral appliances, dentures, removable orthodontics, retainers and protective mouth guards.

Group Pharmaceuticals Ltd shares the same values with bonyf in being at the forefront of oral care innovations, committed to bringing the best oral care science to India. With three facilities across India, manufacturing multiple dosage forms, the facility at Tarapur, near Mumbai, is specially designed and equipped to manufacture moisture sensitive tablets requiring strict humidity control. The facilities are cGMP, PIC/S and WHO compliant. The internal SOPs are designed to be above statutory requirements, enabling them to achieve



PRESS RELEASE Paris, 28 November 2024, 6:00 a.m.

several ISO certifications. A month ago, Group Pharmaceuticals succeeded in the certification as to produce Medical Devices Class a and b, successful testing completed for the first bonyf selected formulation, both cornerstones for a successful alliance between the two oral care manufacturing experts.

The bonyf and Group Pharmaceuticals Ltd alliance brings two R&D oral care-driven manufacturing experts together offering the global golden standard formula for denture cleansing and disinfecting tablets known as NitrAdine® denture tablets. This formula, highly appreciated by dental professionals across Europe and backed by numerous scientific publications, will soon be available to the Indian population under the same trusted European brand name NitrAdine®. The formula holds other successful product applications for which we joined forces are planned as to ensure capacity needs. The licensing agreement activates manufacturing and distribution in India, ensuring accessibility and scalability for a broad and emerging market. Additionally, bonyf is introducing another highly acclaimed product—a denture fixative cream known for its superior quality, also to be produced in India under the same licensing model. Production of these innovative products is planned to begin in early 2025, marking a new era of accessible, high-quality dental care solutions for India.

The alliance enforces not only the global ambition of the bonyf group as leading experts in innovative denture wearer solutions but paves the global competitiveness of the bonyf NitrAdine® cleansing & disinfecting tablets.

Jean Pierre Bogaert, CEO of bonyf: "We are thrilled upon this alliance with Group Pharmaceuticals to bring our advanced dental care products to India. This partnership reflects our commitment to improving oral health standards globally by making scientifically backed, professional-grade solutions accessible to everyone".

For more information, visit **bonyf.com** or contact **investor@bonyf.com**.

bonyfis strengths

- Products with patented formulations
- Produced in Switzerland compliant with stringent international quality regulations
- Proven clinical efficacy
- Commercial presence in 37 countries
- Prospects for solid growth and rapid profitability
- A fast-growing oral and dental care market



PRESS RELEASE

Paris, 28 November 2024, 6:00 a.m.



About bonyf

Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.

For more information about bonyf and its innovative oral care products, please visit www.bonyf.com.

bonyf Jean-Pierre Bogaert investor@bonyf.com

